LYRA
NASDAQ · Pharmaceuticals
Lyra Therapeutics Inc
$0.40
-0.09 (-18.16%)
Financial Highlights (FY 2026)
Revenue
728.6K
Net Income
-44,377,056
Gross Margin
—
Profit Margin
-6,090.9%
Rev Growth
+74.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -6,280.8% | -5,652.8% | 33.2% | 29.0% |
| Profit Margin | -6,090.9% | -5,786.4% | 24.8% | 19.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 728.6K | 418.1K | 681.7K | 558.5K |
| Gross Profit | — | — | 411.1K | 336.8K |
| Operating Income | -45,759,238 | -23,635,970 | 226.6K | 162.2K |
| Net Income | -44,377,056 | -22,922,033 | 169.3K | 107.5K |
| Gross Margin | — | — | 60.3% | 60.3% |
| Operating Margin | -6,280.8% | -5,652.8% | 33.2% | 29.0% |
| Profit Margin | -6,090.9% | -5,786.4% | 24.8% | 19.3% |
| Rev Growth | +74.2% | +74.2% | +3.7% | -9.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.04M | 1.08M |
| Total Equity | — | — | 1.55M | 1.59M |
| D/E Ratio | — | — | 0.67 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -45,536,904 | -24,827,857 | 337.6K | 271.6K |
| Free Cash Flow | — | — | 110.0K | 71.2K |